OncoDEEP offers the world's most complete and comprehensive RNA / DNA / proteins / immunology tests, because 93,4% of treatment decisions are based on combinations of DNA/RNA/PROTEIN tests JF Laes et al., Oncotarget 2018;9; 29
OncoDEEP analyses solid biopsies by combining next-generation sequencing (313 genes), IHCs to study protein expression and additional tests. This complete tumour profiling allows to predict patient response to approved or experimental targeted drugs, immunotherapies and chemotherapies. The NGS panel is accurately designed according to oncologists’ needs in their current practice. Importantly, it also includes an accurate determination of MSI, TMB and LOH. The NGS panel is regularly updated based on new findings reported in literature in order to provide patients with the most cost-effective solution.
NRTK testing is included for some cancer types.
Our immunogram combines five different biomarkers for predicting clinical benefit of immune checkpoint inhibitors (ICIs): PD-L1 protein expression (FDA-approved marker), TMB, CD8+ T-cell infiltration, MSI (FDA-approved marker) and gene alterations leading to sensibility or resistance to ICIs.
OncoDNA publishes regularly in peer-reviewed international journals.
Here below you will find a selection of key publications supporting our clinical expertise in precision oncology.
Genomic Profiling for Patients with Solid Tumors: A Single-Institution Experience ... [READ MORE]
- Annals of Clinical Oncology 2019
The clinical impact of using complex molecular profiling strategies in routine oncology practice ... [READ MORE]
- Oncotarget 2018
A comprehensive and integrated report will be available trhough the OncoSHARE platform. After 7 to 10 days, depending on the test you purchased, the analysis report will be available. In a simple and interactive manner, it will guide you in selecting the most appropriate treatment based on the unique signature of the tumor.
If your question is not addressed above and/or if you would like more information about our solutions, please contact us at firstname.lastname@example.org our Patient and Scientific Support teams are available to answer your questions directly from Monday to Friday. You can also reach us through the chat (icon in the bottom right corner of the window).
OncoSTRAT&GO is an integrated approach that combines the analyses of a solid biopsy (by next-generation sequencing (313 genes), IHCs and additional tests) with the analysis of a blood biopsy. The blood profiling focuses either on the circulating tumor DNA (for deciphering tumor heterogeneity) or in DNA from blood cells (for studying specific germline gene alterations related to BRCAness phenotype that are challenging to detect in FFPE samples). OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, chemotherapies and immunotherapies.Read more
OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.Read more
OncoTRACE by OncoDNA is a test based on circulating tumor DNA (ctDNA) in liquid biopsies (principally blood). It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.
This assay is customized for each patient, as it contains personal cancer-specific markers and variants identified in a previous genomic analysis.
In 2013 OncoDNA became the first company to personalise a specific OncoTRACE test for every patient (a recent publication in 2017 in Nature demonstrates the efficacy of such an approach). Chrisie et al Journal of Clinical Oncology 35, no. 12 (April 20, 2017) 1274-1280.Read more